p.118 抽出テキスト

Europace 2018; 20: 541-547. PMID: 28158428 552. Lieve KV, van der Werf C, Kallas D, et al. Catecholaminergic polymorphic ventricular tachycardia mediated by ryanodine receptor 2: a validated risk stratification. Eur Heart J 2025; ehaf965. PMID: 41416846 553. Tülümen E, Schulze-Bahr E, Zumhagen S, et al. Early repolarization pattern: a marker of increased risk in patients with catecholaminergic polymorphic ventricular tachycardia. Europace 2016; 18: 1587-1592. PMID: 26705564 554. Sumitomo N, Sakurada H, Mugishima H, et al. Adenosine triphosphate terminates bidirectional ventricular tachycardia in a patient with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 2008; 5: 496-497. PMID: 18313614 555. Carinci V, Gamberini L, Coniglio C, et al. Catecholaminergic Polymorphic Ventricular Tachycardia: Challenges During Resuscitation and Post-Cardiac Arrest Care. J Emerg Med 2020; 58: 677-681. PMID: 32204998 556. Roston TM, AlAhmari L, Krahn AD, et al. Choking-induced cardiac arrest unmasks a diagnosis of catecholaminergic polymorphic ventricular tachycardia. HeartRhythm Case Rep 2015; 1: 494-497. PMID: 28491614 557. Hong RA, Rivera KK, Jittirat A, et al. Flecainide suppresses defibrillator-induced storming in catecholaminergic polymorphic ventricular tachycardia. Pacing Clin Electrophysiol 2012; 35: 794-797. PMID: 22553997 558. Cheung CC, Lieve KV, Roston TM, et al. Pregnancy in Catecholaminergic Polymorphic Ventricular Tachycardia. JACC Clin Electrophysiol 2019; 5: 387-394. PMID: 30898243 559. Choi G, Kopplin LJ, Tester DJ, et al. Spectrum and frequency of cardiac channel defects in swimming-triggered arrhythmia syndromes. Circulation 2004; 110: 2119-2124. PMID: 15466642 560. Finocchiaro G, Westaby J, Sheppard MN, et al. Sudden Cardiac Death in Young Athletes: JACC State-of-the-Art Review. J Am Coll Cardiol 2024; 83: 350-370. PMID: 38199713 561. Ostby SA, Bos JM, Owen HJ, et al. Competitive Sports Participation in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia: A Single Center’s Early Experience. JACC Clin Electrophysiol 2016; 2: 253-262. PMID: 29766881 562. Peltenburg PJ, Kallas D, Bos JM, et al. An International Multicenter Cohort Study on β-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation 2022; 145: 333-344. PMID: 34874747 563. O’Donovan CE, Waddell-Smith KE, Skinner JR, et al. Predictors of β-blocker adherence in cardiac inherited disease. Open Heart 2018; 5: e000877. PMID: 30613409 564. Bergeman AT, Lieve KVV, Kallas D, et al. Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation 2023; 148: 2029-2037. PMID: 37886885 565. Kannankeril PJ, Moore JP, Cerrone M, et al. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial. JAMA Cardiol 2017; 2: 759-766. PMID: 28492868 566. van der Werf C, Kannankeril PJ, Sacher F, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol 2011; 57: 2244-2254. PMID: 21616285 567. Watanabe H, Chopra N, Laver D, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 2009; 15: 380-383. PMID: 19330009 568. Padfield GJ, AlAhmari L, Lieve KV, et al. Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant ofβ-blockade. Heart Rhythm 2016; 13: 609-613. PMID: 26416620 569. Aoki H, Nakamura Y. Electrical storms induced by multiple shocks in catecholaminergic polymorphic ventricular tachycardia, spotlight. J Arrhythm 2024; 40: 1214-1216. PMID: 39416250 570. van der Werf C, Lieve KV, Bos JM, et al. Implantable cardioverterdefibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. Eur Heart J 2019; 40: 2953-2961. PMID: 31145795 571. Miyake CY, Webster G, Czosek RJ, et al. Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate. Circ Arrhythm Electrophysiol 2013; 6: 579-587. PMID: 23667268 572. Eckert H, El-Battrawy I, Veith M, et al. Pooled Analysis of Complications with Transvenous ICD Compared to Subcutaneous ICD in Patients with Catecholaminergic Polymorphic Ventricular Arrhythmia. J Pers Med 2022; 12: 536. PMID: 35455651 573. De Ferrari GM, Dusi V, Spazzolini C, et al. Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation. Circulation 2015; 131: 2185-2193. PMID: 26019152 574. Schwartz PJ, Ackerman MJ. Cardiac sympathetic denervation in the prevention of genetically mediated life-threatening ventricular arrhythmias. Eur Heart J 2022; 43: 2096-2102. PMID: 35301528 575. Peltenburg PJ, van den Heuvel LM, Kallas D, et al. Insights into adherence to medication and lifestyle recommendations in an international cohort of patients with catecholaminergic polymorphic ventricular tachycardia. Europace 2024; 26: euae044. PMID: 38349347 576. Okajima K, Kiuchi K, Yokoi K, et al. Efficacy of bilateral thoracoscopic sympathectomy in a patient with catecholaminergic polymorphic ventricular tachycardia. J Arrhythm 2016; 32: 62-66. PMID: 26949433 577. Mori M, Aoki H, Matsuo K, et al. Cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia in the light of the medical situation in Japan. J Arrhythm 2024; 40: 1005- 1009. PMID: 39139908 578. Waddell-Smith KE, Ertresvaag KN, Li J, et al. Cardiac Inherited Disease Group New Zealand. Physical and Psychological Consequences of Left Cardiac Sympathetic Denervation in Long-QT Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia. Circ Arrhythm Electrophysiol 2015; 8: 1151-1158. PMID: 26224781 579. Kaneshiro T, Naruse Y, Nogami A, et al. Successful catheter ablation of bidirectional ventricular premature contractions triggering ventricular fibrillation in catecholaminergic polymorphic ventricular tachycardia with RyR2 mutation. Circ Arrhythm Electrophysiol 2012; 5: e14-e17. PMID: 22334434 580. Shen L, Liu S, Hu F, et al. Electrophysiological Characteristics and Ablation Outcomes in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia. J Am Heart Assoc 2023; 12: e031768. PMID: 38063176 581. Gussak I, Brugada P, Brugada J, et al. Idiopathic short QT interval: a new clinical syndrome? Cardiology 2000; 94: 99-102. PMID: 11173780 582. Anttonen O, Junttila MJ, Rissanen H, et al. Prevalence and prognostic significance of short QT interval in a middle-aged Finnish population. Circulation 2007; 116: 714-720. PMID: 17679619 583. Gallagher MM, Magliano G, Yap YG, et al. Distribution and prognostic significance of QT intervals in the lowest half centile in 12,012 apparently healthy persons. Am J Cardiol 2006; 98: 933-935. PMID: 16996877 584. Guerrier K, Kwiatkowski D, Czosek RJ, et al. Short QT Interval Prevalence and Clinical Outcomes in a Pediatric Population. Circ Arrhythm Electrophysiol 2015; 8: 1460-1464. PMID: 26386018 585. Funada A, Hayashi K, Ino H, et al. Assessment of QT intervals and prevalence of short QT syndrome in Japan. Clin Cardiol 2008; 31: 270-274. PMID: 18543308 586. Hazeki D, Ninomiya Y, Ueno K, et al. Tentative Screening Criteria for Short QT Interval in Children and Adolescents. Circ J 2018; 82: 2627-2633. PMID: 30047504 587. Suzuki H, Horie M, Ozawa J, et al. Novel electrocardiographic criteria for short QT syndrome in children and adolescents. Europace 2021; 23: 2029-2038. PMID: 34179980 588. Mazzanti A, Kanthan A, Monteforte N, et al. Novel insight into the natural history of short QT syndrome. J Am Coll Cardiol 2014; 63: 1300-1308. PMID: 24291113 589. Villafañe J, Atallah J, Gollob MH, et al. Long-term follow-up of a pediatric cohort with short QT syndrome. J Am Coll Cardiol 2013; 61: 1183-1191. PMID: 23375927 590. Giustetto C, Di Monte F, Wolpert C, et al. Short QT syndrome: clinical findings and diagnostic-therapeutic implications. Eur Heart J 2006; 27: 2440-2447. PMID: 16926178 591. Suzuki H, Hoshina S, Ozawa J, et al. Short QT syndrome in a boy diagnosed on screening for heart disease. Pediatr Int 2014; 56: 774-776. PMID: 25335996 592. Jørgensen IN, Skakkebaek A, Andersen NH, et al. Short QTc interval in males with klinefelter syndrome-influence of CAG repeat length, body composition, and testosterone replacement therapy. Pacing Clin Electrophysiol 2015; 38: 472-482. PMID: 25615644 593. El-Battrawy I, Besler J, Liebe V, et al. Long-Term Follow-Up of Patients With Short QT Syndrome: Clinical Profile and Outcome. J Am Heart Assoc 2018; 7: e010073. PMID: 30571592 594. Hancox JC, Whittaker DG, Du C, et al. Emerging therapeutic targets in the short QT syndrome. Expert Opin Ther Targets 2018; 22: 439-451. PMID: 29697308 595. Horie M, Saiki H, Aizawa T, et al. Congenital Short QT Syndrome